When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALLO - Allogene Therapeutics' ALLO-715 nabs accelerated review status in U.S.
Allogene Therapeutics Inc.
The FDA has granted Regenerative Medicine Advanced Therapy ((RMAT)) designation to Allogene Therapeutics' (ALLO) ALLO-715 in relapsed/refractory multiple myeloma.RMAT is akin to Breakthrough Therapy status for drugs/biologics. It provides for the accelerated review of the marketing application and more intensive guidance on development.ALLO shares up 1.2% premarket trading at $32.98.